Clinical Trials Logo
  1. Home
  2. Gastroesophageal Cancer
  3. NCT03490565

PREoperativ Study of Exercise Training — PRESET-RCT  

GastroEsophageal Cancer Clinical Trial

Official title:
PREoperativ Study of Exercise Training-RCT: A Phase 3 Randomized Controlled Trial of Preoperative Exercise Training vs Usual Care During Neoadjuvant Treatment in Patients With Gastroesophageal Cancer

Clinical Trial Summary

Background Patients undergoing resection for gastro-esophageal (GE)-cancer are subjected to high burden of disease and treatment-specific morbidities with potential detrimental impact on survival and quality of life. Exercise training is a promising strategy to improve physical functional before and after tumor resection, but it is not established if this translates into lower risk of peri- and post-operative complications, improved treatment tolerance. Objectives: - To explore the effect a preoperative exercise-training intervention on the risk of treatment failure, defined as the risk of not reaching surgery, in patients diagnosed with operable GE cancer. - To explore the effect of preoperative exercise training on median time to tumor progression (disease free survival), and overall survival - To explore the effect of preoperative exercise training on the risk of treatment complications - To explore the effect of preoperative exercise training on health related quality of life, anxiety and depression,cardiopulmonary fitness, muscle strength, and body composition Subjects and Methods In total, 310 GE-cancer patients will be included in the study and randomly allocated to pre-operative exercise training (n=155) or usual care control (n=155). All participants will undergo 2 study visits; assessed for cardiopulmonary fitness; muscle strength, body composition; blood sample (50 ml); quality of life by questionnaires; physical function; and blood volume profile. Quality of life will be assessed by questionnaires by self-report three times (at 12, 24, and 36 months after diagnosis), and we will collect data from medical records regarding mortality and disease recurrence up to 36 months after diagnosis. Treatment arms: The intervention-group will be prescribed 2-3 weekly supervised exercise training for a total of 12 weeks before surgery during neo-adjuvant chemotherapy. The control group will follow current usual care guidelines. After surgery during adjuvant chemotherapy, both groups will be referred to municipality-based rehabilitation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03490565
Study type Interventional
Source Rigshospitalet, Denmark
Contact
Status Active, not recruiting
Phase N/A
Start date August 16, 2018
Completion date December 31, 2028
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04544046 - Supportive Oncology Care At Home RCT N/A
Not yet recruiting NCT04555304 - Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy Phase 2
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT04099641 - An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Phase 2
Not yet recruiting NCT05431738 - Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) N/A
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Completed NCT03165994 - APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Phase 2
Active, not recruiting NCT03279237 - A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers Phase 1
Completed NCT03321630 - A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies Phase 2
Completed NCT02853474 - Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Phase 3
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT06138223 - The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES) N/A
Active, not recruiting NCT03647969 - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05122091 - Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma Phase 2
Completed NCT03720678 - A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies Phase 1
Completed NCT02317991 - Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Phase 2
Completed NCT02013154 - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Phase 1
Terminated NCT05395052 - FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Recruiting NCT06356311 - A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Phase 3